XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities:      
Net loss from continuing operations $ (3,063,997) $ (6,633,422)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation expense 500 500  
Change in fair value of warrant liability (645,986) 729,889  
Change in fair value of derivative liability (603,322)  
Loss on conversion of note payable 96,646  
Options expense 437 24,266  
Common stock issued for services 1,080,000 4,450,919  
Amortization of debt discount 509,118  
Amortization of right-of-use assets 14,524 7,803  
Changes in operating assets and liabilities:      
Accounts receivable, net 7,371 1,555  
Prepaid expenses and deposits (415,379) (135,013)  
Inventory (4,404)  
Other receivables 95,001 (7,816,763)  
Lease liability (15,041) (7,920)  
Accounts payable (113,913) (544,127)  
Accrued liabilities 97,584 329,876  
Current liabilities (62,390)  
Net cash used in operating activities from continuing operations (2,956,457) (9,659,231)  
Net cash used in operating activities from discontinued operations (530,442)  
Net cash used in operating activities (2,956,457) (10,189,673)  
Cash flows from investing activities:      
Investment in securities (2,500,000)  
Net cash used in investing activities from continuing operations (2,500,000)  
Net cash provided by investing activities from discontinued operations 29,932,589  
Net cash provided by investing activities 27,432,589  
Cash flows from financing activities:      
Repayment of contingent liability (1,246,346)  
Proceeds from loan payable, related party 100,000  
Gross proceeds from issuance of common stock 4,597,999  
Cash dividends paid (12,671,072)  
Proceeds from exercise of warrants 16,567  
Proceeds from exercise of options 9,840  
Net cash provided by (used in) financing activities from continuing operations 4,697,999 (13,891,011)  
Net cash used in financing activities from discontinued operations (5,000)  
Net cash provided by (used in) financing activities 4,697,999 (13,896,011)  
Net change in cash 1,741,542 3,346,905  
Cash at beginning of period 308,096 151,907 $ 151,907
Cash at end of period 2,049,638 3,498,812 $ 308,096
Supplemental disclosure of cash flow information:      
Cash paid for interest 733,694  
Cash paid for taxes  
Supplemental disclosure of non-cash investing and financing activities:      
Conversion of note payable into common stock 411,000  
Equity line of commitment shares issued as offering costs 971,732  
Insurance premium financed 306,152  
Note issued as SOSRx contribution 500,000  
Disposition of assets, related party 492,030  
Issuance of note receivable $ 1,300,000